2024年慢性淋巴细胞白血病的治疗顺序:我们现在在哪里,我们将走向哪里
Alberto Fresa1,2, Idanna Innocenti1, Annamaria Tomasso2
1Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Cancers
|June 19, 2024
概括
新的布鲁顿的氨酸激酶 (BTK) 抑制剂和BCL2抑制剂现在是慢性淋巴细胞白血病 (CLL) 的标准. 本综述探讨了最佳测序策略,以解决这些疗法无法实现长期疾病控制的情况.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化学免疫疗法正在被布鲁顿的氨酸激酶 (BTK) 抑制剂和慢性淋巴细胞白血病 (CLL) 的BCL2抑制剂所取代.
- 这些向疗法显示出显著的疗效,但并不能在所有患者子组中实现长期的疾病控制.
- 解决这种未满足的临床需求对于改善CLL患者的治疗结果至关重要.
研究的目的:
- 对CLL患者的治疗序列模式进行审查和解释.
- 根据当前的证据和正在进行的临床试验,优化治疗策略.
- 识别和解决那些不能通过BTK或BCL2抑制剂实现长期疾病控制的患者类别.
主要方法:
- 关于BTK和BCL2抑制剂在CLL中使用的当前临床证据的审查.
- 分析从前线到复发的治疗顺序.
- 考虑正在进行的临床试验的数据,评估新的治疗算法和分子.
主要成果:
- 在CLL治疗中,BTK抑制剂和BCL2抑制剂的确立疗效.
- 确定需要替代或顺序治疗方法的患者子组.
- 探索各种治疗序列模式,以最大限度地提高治疗效益.
结论:
- 合理化使用BTK和BCL2抑制剂对于优化CLL治疗至关重要.
- 开发有效的治疗顺序策略对于管理未达到最佳反应的患者至关重要.
- 目前正在进行的研究和临床试验旨在完善治疗算法,以改善CLL的长期疾病控制.
关键词:
在 CLL CLL 中.这是一个calabrutinib.伊布鲁丁尼布可以.个性化的个性化的个性化.治疗治疗治疗治疗治疗治疗维尼托克莱克斯 (Venetoclax) 是一个赞努布鲁丁尼布 (Zanubrutinib) 是一种药物.更多相关视频
15:07VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
26.7K
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
2.5K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K